QuidelOrtho Corporation (LON:0A55)

London flag London · Delayed Price · Currency is GBP · Price in USD
43.50
-0.14 (-0.31%)
At close: Jan 31, 2025
-0.31%
Market Cap1.47B
Revenue (ttm)2.00B
Net Income (ttm)-340.09M
Shares Outn/a
EPS (ttm)-5.04
PE Ration/a
Forward PE10.98
Dividendn/a
Ex-Dividend Daten/a
Volume2
Average Volume177
Open43.09
Previous Close43.64
Day's Range43.09 - 43.50
52-Week Range29.91 - 69.67
Betan/a
RSI49.59
Earnings DateOct 29, 2025

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,... [Read more]

Industry Medical - Specialties
Sector Healthcare
Founded 1979
Employees 6,600
Stock Exchange London Stock Exchange
Ticker Symbol 0A55
Full Company Profile

Financial Performance

In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.

Financial numbers in USD Financial Statements

News

QuidelOrtho to Participate in the Baird 2025 Global Healthcare Conference

SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-o...

19 days ago - PRNewsWire

QuidelOrtho Completes Debt Refinancing

SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-o...

26 days ago - PRNewsWire

Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities

SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, is ...

26 days ago - PRNewsWire

QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

SAN DIEGO , Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice Presi...

4 weeks ago - PRNewsWire

QuidelOrtho Launches Certified Analyzer Program

Initiative to expand testing access to underserved U.S. communities SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiativ...

4 weeks ago - PRNewsWire

QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript

QuidelOrtho Corporation (NASDAQ:QDEL) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Brian J. Blaser - President, CEO & Director Joseph M.

5 weeks ago - Seeking Alpha

QuidelOrtho Reports Second Quarter 2025 Financial Results

― Labs revenue grew 4% as reported and 5% in constant currency ― ― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024...

6 weeks ago - PRNewsWire

QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™

SAN DIEGO , July 29, 2025 /PRNewswire/ -- QuidelOrtho earned three awards and top rankings in the 2025 IMV ServiceTrak™ Awards, presented at the Association for Diagnostics & Laboratory Medicine, reco...

7 weeks ago - PRNewsWire

Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast

Episode 49 of QuidelOrtho Science Bytes explores substance use trends, the limits of Narcan, and the evolving challenges facing emergency departments SAN DIEGO , July 24, 2025 /PRNewswire/ -- In emerg...

7 weeks ago - PRNewsWire

QuidelOrtho to Report Second Quarter 2025 Financial Results

SAN DIEGO , July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-o...

2 months ago - PRNewsWire

Real Labs, Actual Decisions With Actionable Six Sigma Metrics

QuidelOrtho Announces Featured ADLM Session SAN DIEGO , July 17, 2025 /PRNewswire/ -- How can actionable, Six Sigma insights improve lab performance? In a featured session at the Association for Diagn...

2 months ago - PRNewsWire

QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)

Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms SAN DIEGO , July 14, 2025 /PRNewswire/ -- QuidelOrtho Corporation...

2 months ago - PRNewsWire

QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs

New executives bring deep expertise to elevate quality and accelerate innovation across global operations SAN DIEGO , July 7, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company"...

2 months ago - PRNewsWire

QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance― ―Company Plans to Discontinue Savanna® Platform Development― ―Company Reaffirms Full Year 2025 Financial Guidance ― ―Company to Hos...

3 months ago - PRNewsWire

QuidelOrtho to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs ...

4 months ago - Business Wire

Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight

New York, USA, May 14, 2025 (GLOBE NEWSWIRE) -- Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight The expansion of the preeclampsia diagnostics market is...

4 months ago - Benzinga

QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)

QuidelOrtho's stock jumped after Q1 2025 earnings beat, but long-term growth remains weak. Check out why QDEL stock is downgraded to hold.

4 months ago - Seeking Alpha

QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript

QuidelOrtho Corporation (NASDAQ:QDEL) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and C...

4 months ago - Seeking Alpha

QuidelOrtho Reports First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...

4 months ago - Business Wire

QuidelOrtho to Report First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setti...

5 months ago - Business Wire